PT - JOURNAL ARTICLE AU - Ramin Nourinia AU - Shintaro Nakao AU - Souska Zandi AU - Sare Safi AU - Ali Hafezi-Moghadam AU - Hamid Ahmadieh TI - ROCK inhibitors for the treatment of ocular diseases AID - 10.1136/bjophthalmol-2017-310378 DP - 2017 Aug 09 TA - British Journal of Ophthalmology PG - bjophthalmol-2017-310378 4099 - http://bjo.bmj.com/content/early/2017/08/09/bjophthalmol-2017-310378.short 4100 - http://bjo.bmj.com/content/early/2017/08/09/bjophthalmol-2017-310378.full AB - The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.